Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.50 Contact Hours.

Acknowledgment of Commercial Support

This educational activity is supported by an educational grant from This activity is supported by an educational grant from Sanofi Genzyme.

Medical Crossfire®: Optimizing the Treat-to-Target Approach in Rheumatoid Arthritis: Translating Clinical Evidence Into Effective Shared Decision-Making

Release Date: August 27, 2020
Expiration Date: August 27, 2021

Activity Overview

The Medical Crossfire®, a PER® signature educational format, is a video-based program in which a panel of distinguished experts engage in spirited discussions and debates on a particular clinical topic. In this activity, 3 key thought leaders use patient cases to illustrate the treat-to-target approach for initial therapy and treatment failure in patients with rheumatoid arthritis. Emerging treatments in current and new anti-inflammatory drug classes are reviewed. Faculty also use patient cases to discuss the use of patient-reported outcomes as an essential tool in the shared decision-making process, in order to optimize treatment and improve health-related quality of life.

Acknowledgment of Commercial Support.

This activity is supported by an educational grant from Sanofi Genzyme.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This online educational activity is directed toward rheumatologists, specialty NPs, specialty PAs, dermatologists, family physicians, primary care physicians, and additional health care providers involved in the treatment and management of RA.

Learning Objectives

Upon successful completion of this educational activity, you should be better prepared to:

  • Review current guidelines for managing DMARD therapy to improve outcomes for patients with RA
  • Evaluate the efficacy and safety of current and emerging DMARDs
  • Develop shared decision-making (SDM) strategies for optimizing patient HRQOL with effective DMARD-based therapies

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.


Jonathan Kay, MD
Jonathan Kay, MD
Professor of Medicine and Population and Quantitative Health Sciences
Timothy S. and Elaine L. Peterson Chair in Rheumatology
University of Massachusetts Medical School
Worcester, MA
Attending Physician
Division of Rheumatology
UMass Memorial Medical Center
Worcester, MA

Disclosures: Grant/Research Support (paid to the University of Massachusetts Medical School): Gilead Sciences, Pfizer, UCB; Consultant: Alvotech Swiss AG, Arena Pharmaceuticals, Boehringer Ingelheim, Celltrion Healthcare, Merck , Mylan, Novartis AG, Samsung Bioepis, Sandoz, UCB.

Jon T. Giles, MD, MPH
Jon T. Giles, MD, MPH
Associate Professor of Medicine
Department of Medicine/Division of Rheumatology
Columbia University, Vagelos College of Physicians & Surgeons
New York, NY

Disclosures: Grant/Research Support: Pfizer; Consultant: Gilead Sciences, Lilly, AbbVie, Bristol Myers Squibb.

Vibeke Strand, MD, MACR, FACP
Vibeke Strand, MD, MACR, FACP
Adjunct Clinical Professor
Division of Immunology and Rheumatology
Stanford University School of Medicine
Palo Alto, CA

Disclosures: Consultant: Abbvie, Amgen, Arena Pharmaceuticals, Asana BioSciences, AstraZeneca, Bayer, Bioventus, Bristol Myers Squibb, Boehringer Ingelheim, Celgene, Celltrion Healthcare, Corrona, Crescendo Bioscience/Myriad Genetics, EMD Serono, Eupraxia Pharmaceuticals, Flexion Therapeutics, Galapagos, Genentech/Roche, Gilead Sciences, Glenmark, GSK, Horizon, Inmedix, Janssen, Kezar Life Sciences, Kypha, Lilly, Merck, Novartis, Pfizer, Regeneron, Royalty Pharma, RRD international, Samsung, Samumed, Sandoz, Sanofi, Selecta Biosciences, Servier, Setpoint Medical, SKK, UCB.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By